Corporation (NYSE: CUB) today announced its Board of Directors has
declared an increase in its regular semiannual cash dividend on common
stock by 12.5 percent from 12 cents to 13.5 cents per share.
Pharmaceuticals, Inc. (NASDAQ: CBST) announced today the U.S. Food
and Drug Administration (FDA) approved ZERBAXA™ (ceftolozane/tazobactam)
for the treatment of adults with complicated urinary tract infections
(cUTI) and complicated intra-abdominal infections (cIAI) caused by
designated susceptible Gram-negative bacteria.
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it will
voluntarily withdraw the contingent value rights (CVRs) it issued under
a Contingent Value Rights Agreement dated October 24, 2013 (CVR
Agreement) from listing on the NASDAQ Global Select Market on February
2, 2015, contemporaneously with their redemption.
Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating
whether members of the board of directors of Cubist Pharmaceuticals,
Inc. (NASDAQ: CBST) breached their fiduciary duties in connection with
the planned merger of the Company with Merck & Co., Inc. Cubist is
engaged in the research, development, and commercialization of
pharmaceutical products for medical needs in the acute care environment.
Sign-up for CUBIST PHARMACEUTICALS INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Cubist Pharmaceuticals, Inc. Over the Proposed Sale of the Company to Merck & Co. Inc. - CBST investment picks
Former United States Securities and Exchange Commission attorney Willie
Briscoe and the securities litigation firm of Powers
Taylor LLP are investigating potential claims against the Board of
Directors of Cubist Pharmaceuticals, Inc. (“Cubist”) (NASDAQ GS:CBST)
concerning the sale to Merck & Co., Inc. Under the terms of the
agreement, Cubist shareholders will receive $102.00 in cash for each
share owned, which is only a 37% premium over the share price just
before the deal was announced and only a slight premium over the 52-week
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.